Table 1.
Incidence of prostate pathology in human prostate epithelium of chimeric grafts after 1–4 months of T+E2 treatment
| Months | n | Normal | SQM | Hyperplasia | HG PIN | Cancer |
|---|---|---|---|---|---|---|
| 1 | 10 | 50% (5/10) | 30%a (3/10) | 30%a (3/10) | 0% (0/10) | 0% (0/10) |
| 2 | 14 | 0% (0/14) | 93%a (13/14) | 22%a (3/14) | 29% (4/14) | 14% (2/14) |
| 3 | 16 | 0% (0/16) | 69%a (11/16) | 50%a (8/16) | 31% (5/16) | 6% (1/16) |
| 4 | 5 | 0% (0/5) | 40%a (2/5) | 80%a (4/5) | 40%a (2/5) | 20%a (1/5) |
| Cumulative incidence | ||||||
| 2–4 | 35 | 0% (0/35) | 74% (26/35) | 43% (15/35) | 31% (11/35) | 11% (4/35) |
Results show diagnosis of entire graft at final autopsy.
a
Some specimens contained multiple diagnoses.